Edesa Biotech, Inc.EDSANASDAQ
Loading
Gross Profit Growth Recovery in ProgressRecovering
Percentile Rank56
3Y CAGR-92.6%
5Y CAGR-56.4%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
-92.6%/yr
vs -60.9%/yr prior
5Y CAGR
-56.4%/yr
Recent deceleration
Acceleration
-31.7pp
Decelerating
Percentile
P56
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 1.58% |
| Q3 2025 | -0.31% |
| Q2 2025 | -5.21% |
| Q1 2025 | 43.15% |
| Q4 2024 | 0.00% |
| Q3 2024 | 100.00% |
| Q2 2024 | -13.26% |
| Q1 2024 | -0.81% |
| Q4 2023 | 96.13% |
| Q3 2023 | -1302.51% |
| Q2 2023 | -203.97% |
| Q1 2023 | -102.50% |
| Q4 2022 | 3866.93% |
| Q3 2022 | 2.14% |
| Q2 2022 | 0.96% |
| Q1 2022 | -0.43% |
| Q4 2021 | 99.16% |
| Q3 2021 | -11244.77% |
| Q2 2021 | -4.70% |
| Q1 2021 | 0.00% |
| Q4 2020 | 100.00% |
| Q3 2020 | -101.67% |
| Q2 2020 | 8.00% |
| Q1 2020 | -3.41% |
| Q4 2019 | -74.65% |
| Q3 2019 | 81953.60% |
| Q2 2019 | -97.22% |
| Q1 2019 | 133.75% |
| Q4 2018 | -51.87% |
| Q3 2018 | 16.64% |
| Q2 2018 | 44.66% |
| Q1 2018 | 5.44% |
| Q4 2017 | 11.75% |
| Q3 2017 | 25.19% |
| Q2 2017 | -69.48% |
| Q1 2017 | -233.39% |
| Q4 2016 | -129.74% |
| Q3 2016 | 3451.57% |
| Q2 2016 | 109.35% |
| Q1 2016 | -123.92% |